Celmatix
Celmatix Inc. is a preclinical-stage women's health biotech focused uniquely on ovarian biology. With a lead "pipeline-in-a-pill" AMHR2 agonist program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix's proprietary multi-omic ovarian health platform, the world's largest of its kind, is the foundation of the company's novel pipeline of first-in-class therapies.
Last updated on
About Celmatix
Founded
2009Estimated Revenue
$10M-$50MEmployees
51-250Funding / Mkt. Cap
$54MCategory
Industry
BiotechnologyLocation
City
New York CityState
New YorkCountry
United StatesCelmatix
Find your buyer within Celmatix